Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H19F3O4 |
| Molecular Weight | 428.4005 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H]1[C@@H](CC2=CC=CC=C2)COC3=CC(=CC=C13)C4=CC(=CC=C4C(O)=O)C(F)(F)F
InChI
InChIKey=NZQDWKCNBOELAI-KSFYIVLOSA-N
InChI=1S/C24H19F3O4/c25-24(26,27)17-7-9-18(23(29)30)20(12-17)15-6-8-19-21(11-15)31-13-16(22(19)28)10-14-4-2-1-3-5-14/h1-9,11-12,16,22,28H,10,13H2,(H,29,30)/t16-,22+/m0/s1
CP-195543 is a selective and potent leukotriene B4 (LTB4) receptor antagonist developed by Pfizer. CP-195543 inhibited human and mouse neutrophil chemotaxis mediated by LTB4. In vivo, after oral administration, CP-195543 blocked LTB4-mediated neutrophil infiltration in guinea pig and murine skin. CP-195543 reduced the clinical symptoms and attendant weight loss in an IL-1-exacerbated murine model of collagen-induced arthritis. Combination of CP-195543 and celecoxib was investigated in phase 2 clinical trials against rheumatoid arthritis, but the drug failed to achieve superiority over placebo, and its development was discontinued.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
204981-48-6
Created by
admin on Mon Mar 31 18:14:05 GMT 2025 , Edited by admin on Mon Mar 31 18:14:05 GMT 2025
|
PRIMARY | |||
|
300000041485
Created by
admin on Mon Mar 31 18:14:05 GMT 2025 , Edited by admin on Mon Mar 31 18:14:05 GMT 2025
|
PRIMARY | |||
|
DB13053
Created by
admin on Mon Mar 31 18:14:05 GMT 2025 , Edited by admin on Mon Mar 31 18:14:05 GMT 2025
|
PRIMARY | |||
|
9823886
Created by
admin on Mon Mar 31 18:14:05 GMT 2025 , Edited by admin on Mon Mar 31 18:14:05 GMT 2025
|
PRIMARY | |||
|
YB1F0V77MK
Created by
admin on Mon Mar 31 18:14:05 GMT 2025 , Edited by admin on Mon Mar 31 18:14:05 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
